Johnson & Johnson agrees to pay up to $5.5 billion to settle nearly 76,000 lawsuits alleging its talc products caused ovarian cancer, ending a decade-long legal battle.
An "early detection blood test" for ovarian cancer is now available in Australia for $1,495, marketed by BCAL Diagnostics. Despite ads targeting all women, the company states it's for high-risk individuals. Experts warn the test is not TGA-approved, has limited data, and a significant false-positive rate, potentially causing distress and unnecessary costs.
Former Wimbledon champion Chris Evert has announced her ovarian cancer has returned for a third time, necessitating surgery and upcoming chemotherapy. She will step back from professional commitments, including Wimbledon, to focus on her recovery, expressing optimism and determination.
Hong Kong TV host Lillian Sze, known for her multilingual skills and emceeing fan events for K-pop stars, has died of ovarian cancer. Her death was announced on social media, prompting tributes from fans and celebrities.
A new ovarian cancer drug, mirvetuximab soravtansine, is now available on the NHS, offering patients more time and a better quality of life. Known as a 'biological missile' or 'Trojan horse' therapy, it targets cancer cells directly, reducing side-effects compared to conventional chemotherapy.
NHS England has approved mirvetuximab soravtansine (Elahere) for women with platinum-resistant ovarian cancer, marking the first new drug for this condition in over 20 years. The treatment, administered every three weeks, delayed cancer progression and prolonged survival by an average of four months in clinical trials.
Hong Kong host Shi Ke-ying revealed her battle with ovarian cancer, with a tumor growing to the size of a five-month pregnancy. The cancer spread to her appendix, requiring a "stoma" to save her life. She shared her condition on IG, seeking support as she undergoes treatment.
Clinical trials presented at the SGO 2026 meeting indicate that the drugs relacorilant and pembrolizumab can significantly improve survival outcomes for patients with platinum-resistant ovarian cancer.
GSK has announced promising early-stage trial results for its cancer treatment Mo-Rez, which showed high efficacy in shrinking tumors for ovarian and endometrial cancer patients. The company plans to move directly to late-stage clinical trials.
